アプタマーベースのフォスファタゼ誘導キメラは受容体チロシンキナーゼ信号伝達を阻害する
PubMedで要約を見る
まとめ
この要約は機械生成です。研究者は,受容体チロシンキナーゼ (RTK) のリン酸化を阻害する新しいアプタマーベースのキメラを開発し,がんに対する新しい治療戦略を提供した. これらのツールは,RTKの活動と細胞の行動を効果的に制御するために,フォスファタゼを勧誘する.
科学分野
- 生物化学
- 分子生物学
- 薬物の発見
背景
- アベラント受容体チロシンキナーゼ (RTK) のリン酸化は,腫瘍の発症,進行,転移を誘導する.
- RTKのリン酸化を調節するための標的分子ツールの開発は,がん治療における重要な課題です.
研究 の 目的
- RTKのリン酸化を抑制する新しいアプタマーベースのキメラの設計と検証.
- タンパク質チロシンフォスファタゼ受容体型F (PTPRF) の活性化に関する作用機構を調査する.
- 新しいフォスファタゼ誘導療法策の開発の基礎を確立する.
主な方法
- 特定のRTK (例えば,c-Met,EGFR) を標的とするアプタマーベースのキメラの構築.
- 様々な細胞系におけるRTKリン酸化を抑制するキメラの有効性の評価
- PTPRFの採用と細胞の生物学的行動への影響の評価
- DNA複素を用いたPTPRFの触媒半径の決定
主要な成果
- アプタマーベースのキメラは,成長因子または自己二酸化によって誘発されるRTKの強力で一般的な阻害を示した.
- キメラはPTPRFによる 細胞の行動を 効果的に調整した.
- PTPRFの触媒半径は,約25.84nmと正確に決定されました.
結論
- この研究は,RTKのリン酸化と細胞過程を選択的に制御するための多岐にわたる方法論を提示しています.
- 開発されたアプタマーベースのキメラは 新種の治療薬の開発に有望な道を示しています
- この研究は,先進的なフォスファテーズ採用戦略を設計するための基礎を提供します.
関連する概念動画
When a ligand binds to a cell-surface receptor, the receptor's intracellular domain changes shape, which may either activate its enzyme function or allow its binding to other molecules. The initial signal is amplified by most signal transduction pathways. This means that a single ligand molecule can activate multiple molecules of a downstream target. Proteins that relay a signal are most commonly phosphorylated at one or more sites, activating or inactivating the protein. Kinases catalyze...
Receptor tyrosine kinases or RTKs are membrane-bound receptors that phosphorylate specific tyrosine on protein substrates. RTKs regulate cellular growth, differentiation, survival, and migration. They contain an extracellular ligand binding domain, a transmembrane domain, and a cytosolic tail with intrinsic kinase activity. Several extracellular signaling molecules activate RTKs in one or more ways and relay the signal downstream. Ligands such as platelet-derived growth factor (PDGF) or...
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Receptor tyrosine kinases:
Receptor tyrosine kinases (RTKs) phosphorylate specific tyrosines on the signaling proteins. RTKs include various growth factor receptors,...
Enzyme-linked receptors are proteins that act as both receptor and enzyme, activating multiple intracellular signals. This is a large group of receptors that include the receptor tyrosine kinase (RTK) family. Many growth factors and hormones bind to and activate the RTKs.
Neurotrophin (NT) receptors are a family of RTKs, including trkA, trkB, and trkC (tropomyosin-related kinase) receptors. TrkA is specific for nerve growth factor (NGF), neurotrophin-6, and neurotrophin-7. TrkB binds...
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

